ARTICLE | Clinical News
rBet v 1: Phase IIb/III data
September 21, 2009 7:00 AM UTC
The double-blind, international Phase IIb/III VO59.08 trial in 483 adult patients showed that 12.5, 25 and 50 µg sublingual tablets of rBet v 1 met the primary endpoint of significantly reducing AASS ...